New biomarker may predict sepsis death risk
NCT ID NCT07356739
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study examined whether levels of Phoenixin-14, a natural molecule with anti-inflammatory effects, can predict which sepsis patients in the ICU are most likely to die. Researchers measured Phoenixin-14 in the blood of 77 adults with septic shock and compared it to standard markers like CRP and procalcitonin. The goal was to see if Phoenixin-14 could serve as a better early warning sign for doctors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If Phoenixin-14 proves to be a reliable marker, it could help doctors better predict which sepsis patients are at highest risk of dying, leading to more timely and aggressive treatment.
- What could go wrong
- This is a small, observational study (77 people) that only looked at a single ICU. The findings need to be confirmed in larger, more diverse groups before they can be used in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
77 people
The number who actually took part.
- Started
-
Apr 2024
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients over the age of 18 admitted to our tertiary intensive care unit with diagnoses of sepsis and/or septic shock
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients over the age of 18 admitted to our tertiary intensive care unit with diagnoses of sepsis and/or septic shock Exclusion Criteria: * Patients under the age of 18, patients who were discharged/transferred or died within 72 hours after being diagnosed with sepsis, patients/relatives who refused to participate in the study, pregnant women, patients with chronic steroid use, endocrinopathy, liver disease, malignancy, or a history of immunosuppression.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Phoenixin-14 molecular downregulation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Firat University Hospital
Elâzığ, 23100, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.